Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BR2022 and BR2022-1 in BRCA-Mutated Advanced Ovarian Cancer
NCT07069335Phase 1Recruiting
- Sponsor
- Boryung
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Boryung. Primary endpoints: Maximum Plasma Concentration (Cmax) and Area Under the Curve over the dosing interval (AUCtau). Started Jun 2025; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07069335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069335.